單株抗體生物相似藥市場規模、佔有率和成長分析：按產品類型、治療領域、應用、最終用戶、分銷管道和地區分類 - 2026-2033 年行業預測

2024年全球單株抗體生物相似藥市值為6.895億美元，預計將從2025年的7.4259億美元成長到2033年的13.4424億美元。預測期（2026-2033年）的複合年成長率預計為7.7%。

由於原料藥專利到期以及對經濟高效、臨床療效相當的治療方法的需求不斷成長，全球單株抗體（mAb）生物相似藥市場正經歷顯著成長。這些產品幾乎是複雜蛋白質藥物的複製品，對於腫瘤、免疫和罕見疾病的治療至關重要，因為單株抗體是價格最昂貴的藥物之一。監管政策的明確和可擴展生產方法的出現正在促進市場准入，推動價格下降並提高患者的用藥可及性。生物相似藥競標的成功案例表明，競爭加劇，這促使臨床醫生轉向更經濟實惠的治療方案。此外，人工智慧在研發階段的應用，透過最佳化設計、提高可預測性和縮短研發週期，提高了效率，最終加快了市場准入速度，並促進了該領域的永續全球成長。

全球單株抗體生物相似藥市場的促進因素

全球單株抗體生物相似藥市場的成長主要得益於旨在緩解患者面臨的經濟和後勤挑戰的擴大患者准入計劃的實施。透過提供共同支付支援、醫療系統導航以及患者和處方醫生的教育，製造商正在提高這些治療方法的可及性，惠及更廣泛的患者群體。這些措施有助於建立醫療服務提供者之間的信任，促進治療的連續性，並最終實現生物相似藥的替代和重複處方。此外，透過製造商、醫療服務提供者和保險公司之間的合作最佳化准入途徑，將進一步加速市場滲透，並培養對單株抗體生物相似藥的持續需求。

全球單株抗體生物相似藥市場的限制因素

全球單株抗體生物相似藥市場面臨源自複雜生產流程的諸多限制因素。這種複雜性造成了技術和營運壁壘，增加了研發難度和生產風險，阻礙了市場成長。對細胞株、純化方法和品質標準的嚴格控制需要專業知識和對先進設施的大量投資。生產過程中的差異性進一步增加了監管機構對可比較性的評估難度，使得高效率的生產規模化難以實現。這阻礙了新進入者，並限制了產能擴張。對供應穩定性和產品品質的擔憂限制了產品的普及，導致支付方和供應商在採購決策上更加謹慎。

全球單株抗體生物相似藥市場趨勢

全球單株抗體生物相似藥市場正經歷顯著成長，新興市場的擴張為其提供了強勁的發展機會。這些新興市場醫療基礎設施的改善和監管政策的進步，為市場創造了巨大的發展空間。製造商積極推動在地化夥伴關係，並採用個人化定價策略，以改善生物相似藥的可及性，以應對不同的報銷情況。此外，有針對性的分銷策略以及與區域相關人員的合作，正在豐富產品系列，增強市場競爭力。為確保永續的市場滲透，各公司正在實施符合當地文化的醫護人員和患者互動策略，並根據各地區不斷變化的醫療保健重點進行調整，最終推動全球生物相似藥市場的需求和成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球單株抗體生物相似藥市場規模：按產品類型和複合年成長率分類（2026-2033 年）

• Bevacizumab生物類似藥
• Rituximab生物相似藥
• 曲妥珠單抗生物相似藥
• 其他單株抗體生物相似藥

全球單株抗體生物相似藥市場規模：按治療領域和複合年成長率分類（2026-2033 年）

• 腫瘤學
• 自體免疫疾病
• 感染疾病
• 呼吸系統疾病
• 其他治療領域

全球單株抗體生物相似藥市場規模：依應用及複合年成長率分類（2026-2033 年）

• 醫院藥房
• 零售藥房
• 專科診所
• 契約製造組織

全球單株抗體生物相似藥市場規模：按最終用戶和複合年成長率分類（2026-2033 年）

• 醫院
• 診斷中心
• 研究機構
• 生物技術和製藥公司
• 其他

全球單株抗體生物相似藥市場規模：按分銷管道和複合年成長率分類（2026-2033 年）

• 直銷
• 批發商
• 網路藥房

全球單株抗體生物相似藥市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Amgen
• AbbVie
• Sandoz
• Teva Pharmaceuticals
• Mylan
• Pfizer
• Samsung Bioepis
• Biocon
• Fresenius Kabi
• Celltrion
• GSK
• Boehringer Ingelheim
• Johnson & Johnson
• Intas Pharmaceuticals
• EMD Serono
• Coherus Biosciences
• Apotex
• Novartis
• Merck
• Sun Pharmaceutical Industries

結論與建議

Global Mab Biosimilar Market size was valued at USD 689.5 Million in 2024 and is poised to grow from USD 742.59 Million in 2025 to USD 1344.24 Million by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global monoclonal antibody (mAb) biosimilar market is witnessing significant growth due to the expiration of original biologic patents and increasing demand for cost-effective, clinically equivalent therapies. These near-identical copies of complex protein drugs are crucial for treating oncology, immunology, and rare diseases, as monoclonal antibodies are among the most expensive medications. As regulatory clarity and scalable manufacturing methods emerge, market entry has become easier, driving price reductions and broader patient access. Increased competition, exemplified by successful biosimilar tender processes, encourages clinicians to switch to more affordable options. Additionally, the integration of artificial intelligence in development enhances efficiency by optimizing design, improving predictability, and accelerating timelines, ultimately enabling faster market entry and sustainable global growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mab Biosimilar market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mab Biosimilar Market Segments Analysis

Global mab biosimilar market is segmented by product type, therapeutic area, application, end-user, distribution channel and region. Based on product type, the market is segmented into Bevacizumab Biosimilars, Rituximab Biosimilars, Trastuzumab Biosimilars and Other Monoclonal Antibody Biosimilars. Based on therapeutic area, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Respiratory Diseases and Other Therapeutic Areas. Based on application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Clinics and Contract Manufacturing Organizations. Based on end-user, the market is segmented into Hospitals, Diagnostic Centers, Research Institutes, Biotechnology & Pharmaceutical Companies and Others. Based on distribution channel, the market is segmented into Direct Sales, Distributors and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mab Biosimilar Market

The growth of the global mAb biosimilar market is significantly driven by the implementation of expanding patient access programs that aim to alleviate financial and logistical challenges faced by patients. By providing support for co-payments, navigating healthcare systems, and educating both patients and prescribers, manufacturers enhance the accessibility of these therapies to a wider audience. Such initiatives build trust among healthcare providers and facilitate continuity of care, ultimately promoting the substitution and repeated prescription of biosimilars. Additionally, collaboration between manufacturers, providers, and payers to optimize access pathways further boosts market penetration and fosters sustained demand for mAb biosimilars.

Restraints in the Global Mab Biosimilar Market

The global market for monoclonal antibody biosimilars faces significant restraints due to the intricate manufacturing processes involved. These complexities create technical and operational hurdles that hinder market growth, as they increase both development difficulties and production risks. The requirement for meticulous management of cell lines, purification methods, and quality standards necessitates specialized knowledge and substantial investment in advanced facilities. Variability in manufacturing can further complicate regulatory assessments of comparability, making it challenging to scale production effectively, which discourages new market entrants and impedes capacity growth. Concerns surrounding supply consistency and product quality lead to cautious procurement choices by payers and providers, limiting widespread adoption.

Market Trends of the Global Mab Biosimilar Market

The global mAb biosimilar market is experiencing significant growth, driven by the expansion of emerging markets where healthcare infrastructure improvement and regulatory advancements are creating robust opportunities. Manufacturers are actively forming local partnerships and adopting tailored pricing strategies to address varying reimbursement scenarios, enhancing access to biosimilars. Additionally, targeted distribution strategies and collaborative efforts with regional stakeholders facilitate portfolio diversification and strengthen competitive positioning. To ensure sustained market uptake, companies are implementing culturally relevant clinician and patient engagement initiatives that align with the evolving healthcare priorities of these regions, ultimately driving demand and growth in the global biosimilar landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Mab Biosimilar Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Bevacizumab Biosimilars
• Rituximab Biosimilars
• Trastuzumab Biosimilars
• Other Monoclonal Antibody Biosimilars

Global Mab Biosimilar Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Respiratory Diseases
• Other Therapeutic Areas

Global Mab Biosimilar Market Size by Application & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Contract Manufacturing Organizations

Global Mab Biosimilar Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes
• Biotechnology & Pharmaceutical Companies
• Others

Global Mab Biosimilar Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Distributors
• Online Pharmacies

Global Mab Biosimilar Market Size & CAGR (2026-2033)

• North America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Therapeutic Area, Application, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMD Serono
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations